<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">DACLIZUMAB</span><br/>(dac'li-zu-mab)<br/><span class="topboxtradename">Zenapax<br/></span><b>Classifications:</b> <span class="classification"> immunosuppressant</span>; <span class="classification">monoclonal antibody</span>; <span class="classification">interleukin-2 receptor antagonist</span><br/><b>Prototype: </b>Basiliximab<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>25 mg/5 mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Immunosuppressant IgG-1 monoclonal antibody produced by recombinant DNA technology. Binds to interleukin-2 (IL-2) receptor
         complex of lymphocytes.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Therefore, daclizumab inhibits IL-2mediated activation of lymphocytes which is the major pathway for cellular immune
         rejection of allografts.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Prophylaxis of acute organ rejection in renal transplant.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to daclizumab; murine protein hypersensitivity, pregnancy (category C), lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Moderate-to-severe renal impairment; allergies, asthma, or history of allergic responses to medications; fungal or herpes
         infection, lymphoma, neoplastic disease, vaccination, varicella, viral infection.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Renal Transplant</span><br/><span class="rdage">Adult/Child:</span> <span class="rdroute">IV</span>
<i>&gt;11 mo,</i> 1 mg/kg. Start first dose no more than 24 h prior to transplant, then repeat q14d for 4 more doses<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Add calculated amount of drug (based on patient's body weight) to 50 mL of NS. Invert infusion bag to dissolve, but do not
                  shake. Discard if diluted solution is colored or has particulate matter.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse diluted drug over 15 min.  
               </p>
</td>
</tr>
</table>
<ul>
<li>Use diluted solution immediately or store at room temperature for 4 h or at 2°8° C (36°46°
            F) for 24 h. Discard after 24 h.
         </li>
<li>Store unopened vials at 2°8° C (36°46° F) and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Edema (general and in extremities), pain, fever, fatigue, shivering, generalized weakness, arthralgia, myalgia, hypersensitivity
      reactions. <span class="typehead">CNS:</span> Tremor, headache, dizziness, insomnia, anxiety, depression. <span class="typehead">CV:</span> Chest pain, hypertension, hypotension, tachycardia, thrombosis, bleeding. <span class="typehead">GI:</span> Constipation, nausea, diarrhea, vomiting, abdominal pain, dyspepsia, abdominal distention, epigastric pain, flatulence, gastritis,
      hemorrhoids. <span class="typehead"> Urogenital:</span>  Oliguria, dysuria, renal tubular necrosis, hydronephrosis, urinary tract bleeding, renal insufficiency. <span class="typehead">Respiratory:</span> Dyspnea, pulmonary edema, cough, atelectasis, congestion, pharyngitis, rhinitis, hypoxia, rales, abnormal breath sounds, pleural
      effusion. <span class="typehead">Skin:</span> Impaired wound healing, acne, pruritus, hirsutism, rash, night sweats. <span class="typehead">Other:</span> Diabetes mellitus, dehydration, blurred vision. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Mycophenolate, cyclosporine</b> may increase mortality. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 120 d. <span class="typehead">Half-Life:</span> 20 d (1138 d). 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor carefully for and immediately report S&amp;S of opportunistic infection or anaphylactoid reaction (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use effective contraception before beginning daclizumab therapy, during therapy, and for 4 mo after completion of therapy.</li>
<li>Avoid vaccinations during daclizumab therapy.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>